2,4-Dimethyl-6-ethyl-1,3,5-triazin | 30362-03-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三嗪类
• 英文名称: 2,4-Dimethyl-6-ethyl-1,3,5-triazin
• 英文别名: 2-Aethyl-4,6-dimethyl-s-triazin；2-ethyl-4,6-dimethyl-[1,3,5]triazine；2-Ethyl-4,6-dimethyl-1,3,5-triazine
• CAS: 30362-03-9
• 化学式: C₇H₁₁N₃
• 分子量: 137.184
• InChiKey: ASGHIBCOCSHGFU-UHFFFAOYSA-N

物化性质

• 沸点：
  87 °C(Press: 43 Torr)
• 密度：
  1.020±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2,4-dimethyl-6-vinyl-s-triazine 在 9-borabicyclo[3.3.1]nonane dimer 作用下， 以 正己烷 为溶剂， 反应 23.0h， 以53%的产率得到2,4-Dimethyl-6-ethyl-1,3,5-triazin
  参考文献：
  名称：

  Hydration with Mercuric Acetate and the Reduction with 9-BBN−H of 2-(1-Alkenyl)-4,6-dimethyl-s-triazines

  摘要：

  Oxymercuration-demercuration of a double bond in conjugation with the 4,6-dimethyl-s-triazin-2-yl substituent as in alkenes la,b gave anti-Markovnikov regioselectivity, which is explained by the electron-withdrawing nature of the triazinyl substituent. However, hydroboration of the conjugated alkenes with 9-BBN-H gave the corresponding alkanes 5a-c under normal workup conditions with or without oxidation. With time and without workup the hydroboration of 1b gave spectral evidence for the formation of intermediates 9-13 resulting from the migration of the 9-BBN moiety from the a-carbon to a ring nitrogen with concurrent formation of an exocyclic double bond to an a-carbon of the ring. Hydrolysis of the intermediates gave 5a-c. A possible mechanism involving successive allylic rearrangements is presented.

  DOI：

  10.1021/jo010784e

文献信息

• HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME
  申请人：LG CHEM, LTD.

  公开号：US20180127385A1

  公开（公告）日：2018-05-10

  The present specification provides a hetero-cyclic compound and an organic light emitting device comprising the same.

  本规范提供了一种杂环化合物和包括该化合物的有机发光器件。
• PI3 KINASE INHIBITORS AND USES THEREOF
  申请人：NIU DEQIANG

  公开号：US20110230476A1

  公开（公告）日：2011-09-22

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用相同的方法。
• Fibre-Reactive Dyes, Their Preparation and Their Use
  申请人：Huntsman International LLC

  公开号：US20150096131A1

  公开（公告）日：2015-04-09

  Reactive dyes of formula (1) wherein Q 1 and Q 2 are each independently of the other hydrogen or unsubstituted or substituted C 1 -C 4 alkyl, A is the radical of a monoazo, polyazo, metal complex azo, anthraquinone, phthalocyanine, formazan or dioxazine chromophore, X is halogen, 3- or 4-carboxypyridin-1-yl, or 3- or 4-carbamoylpyridin-1-yl, Y is vinyl or a radical —CH 2 —CH 2 —U and U is a group removable under alkaline conditions, and q is the number 1 or 2, are suitable for dyeing and printing cellulosic or amide-group-containing fibre materials.

  式子（1）中的反应性染料，其中Q1和Q2各自独立地是氢原子或未取代或取代的C1-C4烷基，A是单偶氮，多偶氮，金属络合偶氮，蒽醌，酞菁，福马赞或二氧杂芥子嗪色团的基团，X是卤素，3-或4-羧基吡啶-1-基，或3-或4-氨基甲酰基吡啶-1-基，Y是乙烯或基团-CH2- -U，U是在碱性条件下可去除的基团，q是数字1或2，适用于染色和印刷纤维素或含酰胺基团的纤维材料。
• Flame-Retardants
  申请人：Pauquet Jean-Roch

  公开号：US20080269383A1

  公开（公告）日：2008-10-30

  Organic polymer compositions can be made flame-retardant by addition of selected organic phosphate and other components, such as known flame-retardants or conventional additives for further improvements, e.g. in name retardancy or light stability.

  有机聚合物组成可以通过添加选择的有机磷酸盐和其他成分（如已知的阻燃剂或传统添加剂）来使其阻燃，以进一步提高阻燃性或光稳定性。
• TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES
  申请人：Cmiljanovic Vladimir

  公开号：US20110275762A1

  公开（公告）日：2011-11-10

  The invention relates to novel therapeutic agents and diagnostic probes. The invention also relates to phosphoinositide 3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor triazine-, pyrimidine- and pyridine-based compoundŝ Formula (I), their stereoisomers, geometric isomers, tautomers, solvates, metabolites, N-oxide derivatives, pharmaceutically acceptable salts, and prodrugs thereof compositions of the new compounds; either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, for treating disorders mediated by lipid kinases. •Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. (Formula I)

  本发明涉及新型治疗剂和诊断探针。本发明还涉及磷脂酰肌醇3-激酶（PI3K）和哺乳动物雷帕霉素靶蛋白酶（mTOR）抑制剂三嗪基、嘧啶基和吡啶基化合物̂公式（I），它们的立体异构体、几何异构体、互变异构体、溶剂化物、代谢物、N-氧化衍生物、药学上可接受的盐以及前药的组合物；新化合物的组合物，可以单独使用或与至少一种额外的治疗剂结合，与药学上可接受的载体；以及使用新化合物的方法，可以单独使用或与至少一种额外的治疗剂结合，用于治疗由脂质激酶介导的疾病。公开了使用公式（I）化合物的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗这种疾病或相关病理条件。(公式I)